The nation of Zimbabwe has turned down a significant American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years over Washington's request for confidential biological samples.
The decision came to light after a government memo from December was leaked, which showed President Emmerson Mnangagwa believed the deal was "skewed".
An official spokesperson has since stated that the United States was requesting biological samples for research and commercial purposes but refused to guarantee the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate task of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated over $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for further talks to reach a agreement agreeable to all parties so the nation's critical HIV treatment initiative can continue.
Wider Background
This development follows a similar case in neighbouring Kenya, where a court suspended a related deal with the US after concerns were filed about the safety of Kenyans' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had administered aid for the US government, but Trump stated its spending was "wasteful" and his government was pursuing government-to-government agreements to enhance transparency and responsibility.
As per statements, Sixteen nations in Africa have so far signed similar agreements, representing more than $18.3bn in committed funds.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration could have provided immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving HIV treatment via US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, with no corresponding promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"In essence, our nation would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be available to our citizens should a future pandemic arise."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its pursuit of one-on-one health agreements were undermining systems previously set up through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This system is designed to guarantee that when a country provides its data, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to develop them."
These objections over the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to further dialogue with our American counterparts on how subsequent collaboration might be arranged in a way that honours the sovereignty and dignity of each country."
Medical Community Reaction
Medical experts stated it acknowledged the government's concerns, but urged that talks need to persist since a large portion of the country's Aids initiatives were funded by international support.
"In cases where technical issues exist, such as those involving information security or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," the group added.
The situation emphasises the ongoing tensions between receiving crucial foreign assistance and safeguarding a country's data in an ever more data-driven world.